Related Experiment Video

Updated: Jun 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Development of early treatment strategies for high-risk myeloma precursor disease in the future

Ola Landgren1, S Vincent Rajkumar

  • 1Medical Oncology Branch, National Cancer Institute, Bethesda, MD, 20892, USA. landgreo@mail.nih.gov

Seminars in Hematology
|January 15, 2011
PubMed

Insights

Smoldering myeloma (SMM) is a precursor to multiple myeloma. Integrating novel markers and monitoring can guide early treatment for high-risk SMM patients, improving outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Smoldering myeloma (SMM) is a precursor to multiple myeloma, characterized by specific M-protein levels or bone marrow plasma cells without organ damage.
  • The natural history of SMM is highly variable, ranging from stable disease to rapid progression, posing challenges for prognosis prediction.
  • Current clinical markers have limitations in accurately predicting individual SMM patient outcomes due to molecular heterogeneity.

Purpose of the Study:

  • To review the current understanding of smoldering myeloma (SMM) and its precursor status to multiple myeloma.
  • To highlight the limitations of existing clinical markers for predicting SMM prognosis.
  • To discuss the potential of integrating novel biological markers and clinical monitoring for developing early treatment strategies for high-risk SMM.

Main Methods:

  • Literature review of smoldering myeloma (SMM) and multiple myeloma.
  • Analysis of current clinical guidelines and risk stratification methods for SMM.
  • Discussion of emerging biological markers and their potential role in SMM management.

Main Results:

  • Smoldering myeloma (SMM) exhibits significant molecular heterogeneity, complicating prognosis prediction with conventional markers.
  • Early treatment for SMM is attractive due to a higher progression rate to multiple myeloma compared to monoclonal gammopathy of undetermined significance (MGUS).
  • The availability of potent drugs with favorable toxicity profiles is crucial for developing effective early treatment strategies.

Conclusions:

  • Accurate prognosis prediction for individual SMM patients remains a challenge due to molecular heterogeneity.
  • Early intervention in high-risk SMM patients is a promising strategy to prevent progression to multiple myeloma.
  • The integration of novel biological markers and enhanced clinical monitoring is essential for advancing early treatment strategies in SMM.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...